High-dose HIV drugs to clear hidden virus
Part of Infections clinical trials.
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 59 years old.
- You have HIV and are taking a triple antiretroviral drug combo that includes an integrase inhibitor (like dolutegravir or raltegravir).
- Your HIV viral load has been undetectable (below 50 copies) for at least 12 months.
- You have never had HIV treatment failure (where the virus became resistant to your meds).
- You have no serious liver, kidney, or bleeding problems, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This trial tests a combination of two drugs that may 'wake up' hidden HIV in your body's cells, so that your immune system or other treatments can then eliminate it. The goal is to shrink the HIV reservoir that remains even when you're on antiretroviral therapy.
This Phase 2 study tests whether UB-421 combined with chidamide can shrink or control the “HIV reservoir,” the hidden HIV in the body that standard treatment may not fully eliminate. It’s mainly for people already on stable HIV medicines with very well-controlled viral levels.
This trial tests a combination of two experimental drugs designed to 'shock and kill' hidden HIV in your body. It is for people with HIV-1 subtype B who are on successful ART and want to explore a potential step toward a cure.
This study measures the “hidden” HIV reservoir in the body and how it relates to blood levels of antiretroviral medicines. It may help doctors better understand why HIV can remain even when the virus is controlled.
This trial tests a new type of medicine that aims to wake up HIV hiding in your body's cells by targeting a viral protein called Tat. The goal is to help find a way to clear the virus completely.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.